

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**Proposed Single Technology Appraisal (STA)**

**Albinterferon alfa-2b for the treatment of hepatitis C**

**Provisional matrix of consultees and commentators**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Novartis (albinterferon alpha-2b)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action on Hepatitis C</li> <li>• Addiction Today (Addiction Recovery Foundation)</li> <li>• Afiya Trust</li> <li>• AVERT</li> <li>• Black Health Agency</li> <li>• British Liver Trust</li> <li>• British Organ Donor Society (BODY)</li> <li>• Chinese National Healthy Living Centre</li> <li>• Compass UK</li> <li>• Counsel and Care</li> <li>• Drugs Action</li> <li>• Drugscope</li> <li>• Equalities National Council</li> <li>• European Association for the treatment of Addiction UK</li> <li>• GMFA - The Gay Men's Health Charity</li> <li>• Haemophilia Alliance</li> <li>• Haemophilia Society</li> <li>• Hepatitis A –Z</li> <li>• Hepatitis C Trust</li> <li>• Mainliners</li> <li>• Muslim Council of Great Britain</li> <li>• Muslim Health Network</li> <li>• NAM Publications</li> <li>• National AIDS Trust</li> <li>• Positively Women</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Transplant Support Network</li> <li>• Transplant Trust</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• NHS Purchasing and Supply Agency</li> <li>• NHS Quality Improvement Scotland</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Possible comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> <li>• Roche (ribavirin, peginterferon alfa)</li> <li>• Schering-Plough (ribavirin, peginterferon alfa)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Centre for Sexual Health &amp; HIV Research</li> <li>• Foundation for Liver Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute of Health Research</li> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Research Institute for the Care of Older People</li> </ul> <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> <li>• Evidence Review Group tbc</li> <li>• National Institute for Health Research</li> </ul>

National Institute for Health and Clinical Excellence

Provisional matrix for the proposed technology appraisal of albinterferon alpha-2b for the treatment of hepatitis C

Issue date: March 2010

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• UK Coalition of People Living with HIV and AIDS</li> <li>• Youth Net</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Clinical Microbiologists</li> <li>• Association of Medical Microbiologists</li> <li>• Association of Nurses in Substance Abuse</li> <li>• Association of Surgeons of Great Britain</li> <li>• British Association for Services to the Elderly</li> <li>• British Association for Sexual Health and HIV</li> <li>• British Association for the Study of the Liver</li> <li>• British Association for the Study of the Liver Nurses Forum</li> <li>• British Geriatrics Society</li> <li>• British Infection Society</li> <li>• British Liver Nurses Forum</li> <li>• British Society of Gastroenterology</li> <li>• British Transplantation Society</li> <li>• British Viral Hepatitis Group</li> <li>• Haemophilia Nurses Association</li> <li>• Health Protection Agency</li> <li>• Hepatitis Nurse Specialist Forum</li> <li>• Infection Control Nurses Association</li> <li>• Medical Foundation for AIDS &amp; Sexual Health</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine – Intellectual Disabilities Forum</li> <li>• Society for General Microbiology</li> <li>• United Kingdom Clinical Virology Network</li> <li>• United Kingdom Haemophilia Centre</li> </ul>	<p>Health Technology Assessment Programme</p> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• tbc</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• tbc</li> </ul>

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p>Doctors' Organisation</p> <ul style="list-style-type: none"> <li>• United Kingdom Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• NHS East Riding of Yorkshire</li> <li>• NHS Stock on Trent</li> <li>• Welsh Assembly Government</li> </ul>	

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### Definitions:

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

#### Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.